Insider · CIK 0001779978
Praveen P. Tipirneni
Files at TECX (Tectonic Therapeutic, Inc.), BBOT (BridgeBio Oncology Therapeutics, Inc.). First filing -, latest -.
In brief
Praveen P. Tipirneni files SEC Form 4 as director at TECX (Tectonic Therapeutic, Inc.), and also at BBOT (BridgeBio Oncology Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Praveen P. Tipirneni has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +31,675 | $0.00 | $0 | 31,675 | Jun 18, 2026 |
| Jun 9, 2026 | TECX Tectonic Therapeutic, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,200 | $0.00 | $0 | 10,200 | Jun 10, 2026 |
| Aug 26, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +52,269 | $0.00 | $0 | 52,269 | Aug 28, 2025 |
| Jun 9, 2025 | TECX Tectonic Therapeutic, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,200 | $0.00 | $0 | 10,200 | Jun 11, 2025 |
Questions about Praveen P. Tipirneni
Answered from the filings on this page, as of the latest one.
Is Praveen P. Tipirneni buying or selling?
Praveen P. Tipirneni has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Praveen P. Tipirneni's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Praveen P. Tipirneni has 0.
Where does Praveen P. Tipirneni file Form 4?
Praveen P. Tipirneni has filed Form 4 at TECX (Tectonic Therapeutic, Inc.); BBOT (BridgeBio Oncology Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.